Bob Evans Farms
said same-store sales fell 5.8% in April compared with a year ago. For the fourth quarter, the company expects earnings of 16 cents a share, while for the full year 2005, the company forecasts earnings of $1.04 a share. Analysts were expecting earnings of 22 cents a share for the fourth quarter and $1.11 a share for the full year, according to Thomson First Call. The stock was down 81 cents, or 3.63%, to $21.50 in after-hours trading.
said it earned $600,000, or 3 cents a share, for the first quarter ended March 31, compared with $64,000, or breakeven, a year ago. Revenue for the quarter was $23.8 million. Excluding certain items, the company earned $2 million, or 9 cents a share. Analysts expected earnings of 9 cents a share on revenue of $23.6 million. For the second quarter, the company expects to earn 3 cents to 4 cents on revenue in the range of $24.1 million to $24.5 million. Adjusted earnings are expected to be 7 cents to 8 cents a share, which is below Wall Street's forecast of 12 cents. The stock was down 98 cents, or 9.11%, to $9.78 in after-hours trading.
it earned $2.4 million, or 11 cents a share, for the first quarter ended March 31, versus $775,000, or 5 cents a share, a year ago. Revenue for the quarter was $37.5 million. Analysts expected profits of 11 cents a share on revenue of $37 million, according to Thomson First Call. For the second quarter, the company expects earnings of 11 cents a share on revenue of $37.5 million. For the full year, it expects to earn 72 cents to 74 cents a share on revenue in the range of $167 million to 170 million. Wall Street was expecting profits of 16 cents a share on revenue of $40 million for the second quarter and 71 cents a share on sales of $165.7 million for the full year. The stock was down $1.37, or 9.53%, to $13 in after-hours trading.
said it earned $33.1 million, or 36 cents a share, for the first quarter ended March 31, compared with $19.3 million, or 28 cents a share, a year ago. Revenue for the quarter was $147.2 million. The stock was unchanged at $14.87.
said that its phase II clinical study of its DG031 results demonstrate that it works to correct perturbation caused by genetic risk factors for heart attack and lowers the levels of established biomarkers for the risk of heart attacks. The company has published the results in the Journal of the American Medical Association. The stock was up 31 cents, or 4.17%, to $7.75 in after-hours trading.